



July 10, 2024

To,
Listing/ Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIP CODE: 543748

To,
Listing/ Compliance Department
**National Stock Exchange of
India Limited**
"Exchange Plaza", Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
SYMBOL: AARTIPHARM

Dear Sir/Madam,

Sub: Clarification on announcement dated May 31,
2024.

This is with reference to the disclosure given by the Company on May 31, 2024 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") with regards to closure of manufacturing activities at our Dombivli plant.

As per the clarification sought by the National Stock Exchange of India Limited ("NSE") vide its email dated July 08, 2024 on the aforementioned intimation, the details required under Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are given in Annexure 'A' attached to this letter.

Please take the same on your records.

Thanking you,

Yours faithfully,

For AARTI PHARMALABS LIMITED

NIKHIL NATU
COMPANY SECRETARY
ICSI M. NO. A27738

Encl.: a/a.

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

Annexure A

Sr. No.	Particulars	Remarks
1.	Name of the authority	Maharashtra Pollution Control Board Regional Office, Kalyan ('MPCB')
2.	Nature and details of the action(s) taken, initiated or order(s) passed	Closure Directions u/s 33A of the Water (Prevention & Control of Pollution) Act, 1974 and u/s 31A of the Air (Prevention & Control of Pollution) Act, 1981.
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	May 31, 2024
4.	Details of the violation(s)/contravention(s) committed or alleged to be committed	Compliance with the MPCB Interim Directions on fuel usage.
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	The plant's turnover was Rs. 34.72 crores, which is 1.87% of turnover and 1.98% of Networth.

For AARTI PHARMALABS LIMITED

NIKHIL NATU
COMPANY SECRETARY
 ICSI M. NO. A27738